Taipei Medical University Institutional Repository:Item 987654321/61136
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 45069/58245 (77%)
造访人次 : 2369749      在线人数 : 177
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/61136


    题名: 以深度蛋白體分析探討化療藥物pemetrexed與paclitaxel於非小細胞肺癌之調控分子機制
    An in-depth proteomics investigation of the perturbed mechanism underlying pemetrexed and paclitaxel treatment in non-small-cell lung cancer
    作者: 徐宇慧
    Hsu, Yuu-Hueih
    贡献者: 臨床藥物基因體學暨蛋白質體學碩士學位學程
    韓嘉莉
    关键词: 非小細胞肺癌;化學治療;免疫;膜蛋白體
    NSCLC;Chemotherapy;Immune;Membrane proteomics
    日期: 2016
    上传时间: 2021-11-22 16:30:14 (UTC+8)
    摘要: 非小細胞肺癌在全世界及台灣都是發生率佔前五名,致死率第一名的癌症;目前鉑金類藥物搭配第三代化療藥,包括pemetrexed及taxane類藥物之雙重療法為建議之非小細胞肺癌第一線治療。而在我們的團隊中發現,使用pemetrexed加上cisplatin作為第一線治療的病患,雖然腫瘤不像taxane類藥物加上cisplatin治療時會有顯著的減小,但有較少的副作用、較好的生活品質及較長的存活期。而在這個現象背後的分子機轉還沒有被全面性的探討過。在此我們使用蛋白質體學的手法,包括膜蛋白萃取技術、iTRAQ定量技術及逆向Stage-Tip層析,最後使用液相層析串聯質譜儀分析非小細胞肺癌病人之周邊血單核球。
    1850, 2093及2166個蛋白質在三個實驗中從六個病人當中被分析出來,四個病人為接受pemetrexed搭配cisplatin療法及兩名病人為接受taxane搭配cisplatin療法。分析四個pemetrexed治療病人有相同調控的蛋白質得到這些蛋白質可能與血小板活化、細胞附著及免疫反應有關;而用同樣的手法分析兩個taxane治療病人得到能與蛋白質轉譯及下降的免疫反應有關。比較腫瘤復發存活期特別長的病人及特別短的病人發現,存活期特別短的病人身上發現上升的CD3, CD4, CD45, MHC class II接受器, LCK及PI3K分子,可能和上調的表意反應有關;而在存活期特別長的病人上得到上升的CD3及CD4,下調的CD45、ZAP70及PI3K,顯示一個較平較平衡的免疫狀態。另外在EGFR突變接受taxane治療的病人身上偵測到下降的MHC class I和II及integrin分子,暗示免疫反應在這樣病人的下調。由本次研究中發現許多從未被發表過化療藥物對病人單核球細胞的影響,形成新的假說值得作進一步的探討。
    Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer worldwide. Currently, pemetrexed, combining with casplatin, has been used as the first-line treatment for patients carrying wild-type EGFR with locally advanced or metastatic NSCLC. Taxanes are another commonly used drugs for chemotherapy. Our team found that patients received pemetrexed treatment showed better clinical outcome and survival rate; however, the underlying perturbed mechanism has not yet been examined in the proteomic scope of view. To unravel the perturbed mechanism upon pemetrexed and paclitaxel treatment, we performed membrane proteomics analysis on patient’s purified peripheral blood mononuclear cells (PBMCs) by iTRAQ labeling, reversed-phase StageTip fractionation and LC-MS/MS analysis.
    1850, 2093 and 2166 membrane proteins were identified in three sets of experiments from 6 patients’ PBMCs. Four of them were treated by pemetrexed plus cisplatin first-line treatment while two of them were treated by taxane plus cisplatin first line treatment. The molecular function analysis of the 120 and 44 proteins that had common expression profile in at least three patients in pemetrexed group and all two taxane treated patient respectively were conducted. Platelet and integrin activating functions were enriched in pemetrexed group and increased transcription activities were over-represented in taxane group. Immunophenotyping and pathway analysis results correlating with the clinical outcomes suggested that increased CD45RA, CD3, MHC class II molecule and unchanged integrins after first line treatment might suggest a disrupted immune status and linking to unfavorable outcomes. Up-regulated CTLA4 and integrin levels but unchanged CD45RA, CD3, MHC class II molecule after first line treatment might predict favorable effects. These new hypotheses are worth further investigation in more eligible patients.
    描述: 碩士
    指導教授:韓嘉莉
    数据类型: thesis
    显示于类别:[臨床藥物基因體學暨蛋白質體學碩士學位學程] 博碩士論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML1471检视/开启


    在TMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    著作權聲明 Copyright Notice
    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏,包含體系內各式學術著作及學術產出。秉持開放取用的精神,提供使用者進行資料檢索、下載與取用,惟仍請適度、合理地於合法範圍內使用本平台之內容,以尊重著作權人之權益。商業上之利用,請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台,視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例,並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者,煩請權利人通知本平台維護人員([email protected]),將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈